Sprycel (dasatinib) — Medica
Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL)
Initial criteria
- Patient has Philadelphia chromosome-positive acute lymphoblastic leukemia.
Reauthorization criteria
- Patient continues to meet initial criteria.
Approval duration
1 year